ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pfizer has licensed Kosan Biosciences' motilin agonist program, including Kosan's KOS-2187, which is being studied in gastrointestinal diseases. Kosan will receive an up-front payment of $12.5 million and could receive payments up to $250 million, plus royalties, for the successful development of the compound for one indication. Pfizer has also expanded its therapeutic antibody collaboration with MorphoSys to the end of 2011. The potential value of the collaboration to MorphoSys is now more than $100 million, plus royalties.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter